Restart Life Sciences Corp.

NMLSFOTCHealthcare● Active

$0.04

+$0.00(+0.00%)

Market Cap$1279264

P/E Ratio—

52W High$0.12422

52W Low$0.0101

Avg Volume847

Open$0.12

Beta-0.81

Free Cash Flow Financials Revenue

Restart Life Sciences Corp. (NMLSF) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

NMLSF · free cash flow · updated Jun 15, 2026

Core FCF metrics

NMLSF · FCF · TTM · margin & CAGR

Free cash flow was −$717,219 for FY2025 (fiscal year ending 2025-12-31), down 899.3% year-over-year

FY2025 Free Cash Flow−$717,219▼ -899.3% YoY

Trailing 12M (TTM)−$720,384.4trailing 4 quarters sum

FCF Margin——

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 15, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

NMLSF · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest−$717,219(0M)−$717,219▼ 899.3%—

FY2024−$71,773(0M)−$71,773▲ +74.1%—

FY2023−$277,531(0M)−$277,531▲ +80.8%—

FY2022−$1.4M(0M)−$1.4M▲ +25.8%—

FY2021−$1.9M(0M)−$1.9M▼ 361.1%—

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

NMLSF · P/FCF · FCF yield · FCF per share

Restart Life Sciences Corp. (NMLSF) reported negative free cash flow of −$0.00B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

NMLSF · cash flow statement · operating / investing / financing

For FY2025, Restart Life Sciences Corp. generated −$0.7M in operating cash flow and spent 0M in capital expenditures, yielding −$0.7M in free cash flow.

Operating Activities

−$0.7M

Cash from core business operations

2025-12-31

Investing Activities

+$0.0M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

+$2.3M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF (−$0.7M) − |CapEx| (0M) = FCF (−$0.7M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

NMLSF vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Restart Life Sciences Corp.YOU

NMLSF

−$717,219-899.3%—

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Restart Life Sciences Corp. (NMLSF) reported free cash flow of −$717,219 for FY2025 (fiscal year ending 2025-12-31), down 899.3% year-over-year.

Restart Life Sciences Corp. has reported negative free cash flow in recent periods, indicating capital expenditures have exceeded operating cash flow. Data available for 15 fiscal years.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

NMLSF free cash flow · 8 questions

Restart Life Sciences Corp. free cash flow was −$717,219 for FY2025, down 899.3% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$720,384.4.

NMLSF free cash flowNMLSF FCFNMLSF FCF 2025NMLSF free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Restart Life Sciences Corp. · Restart Life Sciences Corp. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 15, 2026